Primary progressive multiple sclerosis

This study is testing whether a subcutaneous (under the skin) injection of ocrelizumab works as well as the standard intravenous (IV) infusion for people with relapsing or primary progressive multiple sclerosis. The trial will compare how the drug is absorbed, its safety, and its…

This study followed 1,710 people with relapsing or primary progressive multiple sclerosis who were prescribed ocrelizumab (Ocrevus) as part of their normal care. Researchers tracked symptoms like fatigue, mobility, and cognition, as well as side effects, to see how well the drug …

This early-stage trial tested a new cell therapy called DUOC-01, made from donated umbilical cord blood, in 20 adults with primary progressive multiple sclerosis (PPMS). The cells were injected into the spinal fluid to see if it was safe. Researchers also looked for early signs o…

This Phase 3 trial tested whether the oral drug tolebrutinib can delay disability progression in people with primary progressive multiple sclerosis (PPMS). 767 adults with PPMS received either tolebrutinib or a placebo. The study measured time to confirmed disability worsening ov…

This phase 2 trial tested a liquid suspension of gold nanocrystals, called CNM-Au8, in 33 people with relapsing multiple sclerosis. The goal was to see if the treatment could improve energy metabolism in brain cells, measured by a special MRI scan. Participants took the drug by m…

This trial tests whether N-acetyl cysteine (NAC), an antioxidant supplement, can reduce fatigue in people with progressive multiple sclerosis. Participants take NAC or a placebo three times daily for four weeks, and researchers measure changes in fatigue scores and brain chemistr…

This trial investigates whether a non-invasive technique called transcranial direct current stimulation (tDCS) can help with fatigue, depression, anxiety, and cognitive problems in people with multiple sclerosis (MS). tDCS uses a weak electrical current applied to the scalp to ge…

This study follows 66 people with primary progressive multiple sclerosis (PPMS) and healthy volunteers for two years to understand how thinking and memory change over time. Participants take cognitive tests and undergo MRI scans to see how brain tissue damage relates to mental de…

This study used a special eye camera (adaptive optics) to look at blood vessel inflammation in the retina of 50 people with multiple sclerosis (MS) and healthy volunteers. The goal was to see if this inflammation differs between MS types and could serve as an early marker of dise…

This study looked at 46 people with progressive multiple sclerosis who have more weakness on one side of their body. Researchers used MRI scans to see how damage in the brain and spinal cord relates to muscle strength in each limb. The goal was to better understand what causes ph…

This study analyzed MRI scans from 732 people with primary-progressive multiple sclerosis who took part in the ORATORIO trial. Researchers wanted to see if ocrelizumab changes a part of the brain called the choroid plexus, which may be involved in inflammation. The study was obse…

This study reviewed medical records of 800 multiple sclerosis patients to see if gender, race, or socioeconomic status affected how quickly they started Ocrelizumab or how well it worked. Researchers looked at relapse rates and MRI changes over 12 to 24 months. The goal was to id…

This completed study measured two proteins in the blood—neurofilament light chain and GFAP—that can signal nerve damage. Researchers compared 15 people with atypical MS, 30 with typical MS, and 15 healthy controls to see if these markers differ. The goal was to better understand …